X. Fang

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

R. Houot, M. Kersten, I. Flinn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC

Qian Jiang, D. Ma, B. Tan, 2019, Medicine.

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Michael L. Wang, C. Jacobson, J. Rossi, 2020 .